מונטהלוקאסט אינובמד 5 מ"ג

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

MONTELUKAST AS SODIUM 5 MG

Commercializzato da:

INOVAMED LTD

Codice ATC:

R03DC03

Forma farmaceutica:

CHEWABLE TABLETS

Via di somministrazione:

PER OS

Prodotto da:

SYNTHON B.V., NETHERLANDS

Gruppo terapeutico:

MONTELUKAST

Indicazioni terapeutiche:

Montelukast Inovamed is indicated in pediatric patients 6 to 14 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.Montelukast Inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montelukast Inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montelukast Inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 to 14 years of age.

Data dell'autorizzazione:

2012-01-01